Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer (LISA)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Ontario Clinical Oncology Group (OCOG)
ClinicalTrials.gov Identifier:
NCT00463489
First received: April 19, 2007
Last updated: February 24, 2014
Last verified: February 2014

April 19, 2007
February 24, 2014
August 2007
May 2018   (final data collection date for primary outcome measure)
Disease-free survival [ Time Frame: 8 years ] [ Designated as safety issue: No ]
Disease-free survival
Complete list of historical versions of study NCT00463489 on ClinicalTrials.gov Archive Site
  • Overall survival [ Time Frame: 8 years ] [ Designated as safety issue: No ]
  • Distant disease-free survival [ Time Frame: 8 years ] [ Designated as safety issue: No ]
  • Weight at 6, 12, 24, 36, 48 and 60 months compared to baseline [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Health-related quality of life at 6, 12, 24, 36, 48 and 60 months compared to baseline [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Other medical endpoints such as diabetes, cardiovascular disease, arthritis, fasting biomarkers at 12 months compared to baseline (for women participating in a biospecimen substudy) [ Time Frame: 8 years ] [ Designated as safety issue: No ]
  • Compliance with study procedures. [ Time Frame: 8 years ] [ Designated as safety issue: No ]
  • Overall survival
  • Distant disease-free survival
  • Weight at 6, 12, 24, 36, 48 and 60 months compared to baseline
  • Health-related quality of life at 6, 12, 24, 36, 48 and 60 months compared to baseline
  • Other medical endpoints such as diabetes, cardiovascular disease, arthritis, fasting biomarkers at 12 months compared to baseline (for women participating in a biospecimen substudy)
  • Compliance with study procedures.
Not Provided
Not Provided
 
Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer
Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer

The primary objective of this trial is to evaluate the effect of the addition of a 2 year, centrally delivered individualized, telephone-based lifestyle intervention focusing on weight management to a mailed educational intervention on Disease Free Survival in post-menopausal women with early stage breast cancer (hormone receptor positive), BMI ≥24-<40 kg/m2, who are receiving standard letrozole adjuvant therapy.

The primary objective of this trial is to evaluate the effect of the addition of a 2 year, centrally delivered individualized, telephone-based lifestyle intervention focusing on weight management to a mailed educational intervention on Disease Free Survival in post-menopausal women with early stage breast cancer (hormone receptor positive), BMI ≥24-<40 kg/m2, who are receiving standard letrozole adjuvant therapy. The telephone intervention will involve 19 phone calls, as well as mailings and a participant manual; women will be asked to lose up to 10% of their weight by reducing their caloric and fat intake (by 500-1000 kcal/day, 20% calories fat) and increasing their moderate physical activity (to 150-200 minutes/week). Secondary outcomes include overall survival, distant disease-free survival, weight change, health-related quality of life (HRQOL), selected non-cancer medical events and biologic factors (notably insulin). Approximately 2,150 women will be enrolled; follow-up will continue until target event rates have been met (anticipated 4-6 years after completion of the intervention). This sample size will provide 80% power (type 1 error 0.05 2-tailed) to detect a hazard ratio (HR) for DFS of 0.74-0.76 in the weight loss intervention arm.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Breast Cancer
  • Behavioral: Lifestyle intervention
    Women randomized to the lifestyle intervention arm will receive an intervention program that consists of individual weight loss, diet and physical activity goals, incorporated into a 2 year standardized, structured telephone and mail-based intervention. In addition to diet and physical activity, the intervention will address behavioural and motivational issues relating to weight management including maintaining motivation, overcoming obstacles to success, relapse prevention, emotional distress, stress and time management.
  • Behavioral: Mail-based
    Participants will receive a standardized mail-based intervention focussing on healthy living. This will include mailings at study entry as well as a two year subscription to health magazine.
  • Active Comparator: Mail-based
    Participants will receive a standardized mail-based intervention focussing on healthy living. This will include mailings at study entry as well as a two year subscription to health magazine.
    Intervention: Behavioral: Mail-based
  • Experimental: Individualized Lifestyle Intervention
    Women randomized to the individualized lifestyle intervention arm will receive an intervention program that consists of individual weight loss, diet and physical activity goals, incorporated into a 2 year standardized, structured telephone and mail-based intervention. In addition to diet and physical activity, the intervention will address behavioural and motivational issues relating to weight management including maintaining motivation, overcoming obstacles to success, relapse prevention, emotional distress, stress and time management.
    Intervention: Behavioral: Lifestyle intervention
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
2150
May 2018
May 2018   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Post-menopausal woman with a diagnosis of invasive breast cancer (T1-3,pN0-2,M0) for which definitive surgery was performed during the previous 36 months.
  • On adjuvant hormonal therapy with letrozole at time of randomization (either as initial adjuvant hormonal therapy or after a switch from tamoxifen or other hormonal therapy).
  • BMI ≥ 24 kg/m2.
  • Medical, surgical or radiation oncologist agrees to subject participation in a diet and physical activity program.

Exclusion Criteria:

  • Life expectancy less than five years.
  • Self-reported inability to walk at least 2 blocks (at any pace).
  • Insulin requiring diabetes (telephone directed diet and physical activity changes would be difficult in this population without close coordination with the treating physician). Non-insulin requiring diabetics are eligible for the study.
  • Serious digestive and/or absorptive problems, including inflammatory bowel disease and chronic diarrhea that preclude adherence to the study diet.
  • Cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity. Moderate arthritis that does not preclude physical activity is not a reason for ineligibility.
  • Psychiatric disorders or conditions that, in the opinion of the investigator, would preclude participation in the study intervention (e.g. untreated major depression or psychosis, substance abuse, severe personality disorder).
  • Patients on aromatase inhibitors other than letrozole at study entry.
  • Known recurrence of breast cancer (local, regional or distant) at any time prior to study entry.
  • History of other malignancies except: adequately treated non-melanoma skin cancer, curatively treated in situ carcinoma of the cervix, or other solid tumours curatively treated with no evidence of disease for ≥ 5 years. Prior in situ cancer of the breast is not a reason for exclusion.
  • Patients not fluent in either English or French (spoken and written).
  • Patient unwilling or unable to provide informed consent.
Female
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
 
NCT00463489
OCOG-2007-LISA
No
Ontario Clinical Oncology Group (OCOG)
Ontario Clinical Oncology Group (OCOG)
Novartis Pharmaceuticals
Principal Investigator: Pamela J Goodwin, MD, MSc UHN-Mount Sinai Hospital, Toronto, ON
Ontario Clinical Oncology Group (OCOG)
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP